UK Rebate Mechanism Could Force Market Withdrawals, Warns BGMA

Generics Association Cautions That Removing Competition Could Cost NHS Billions

A UK rebate mechanism designed to increase access to new treatments and promote affordability “could actually be denying the NHS billions of pounds of annual savings due to the impact it is having on branded generics and biosimilars,” according to the BGMA.

Blue and orange capsule on a pound coin
The BGMA says reduced competition could be costly for the NHS • Source: Shutterstock

More from Policy & Regulation

More from Generics Bulletin